DUB targets explored
In the DUB field
Commercializing expert research into
Dubs and Ubiquitin pathway
Mission Therapeutics’ strategy is to create value by advancing its pipeline programs through early clinical development, and preferentially with a patient selection strategy to enhance the probability of demonstrating early signs of efficacy. Selected programmes may be advanced in partnership with other pharmaceutical companies.
- Mission Therapeutics and AbbVie sign DUBs Collaboration in Alzheimer’s and Parkinson’s Disease15th November 2018
- Mission Therapeutics Strengthens Clinical Development Team with Appointment of Dr Judit Molnar as Senior Director, Translational Medicine4th September 2018
- Mission Therapeutics Appoints Dr Bobby Soni to its Board of Directors8th March 2018